REGISTER: ISHRM Webinar on HIPAA Modifications, ICE Presence Nov. 13
Legal experts from HeplerBroom LLC will lead a
Nov. 13 webinar addressing the impact of recent modifications to HIPAA on healthcare providers. The noon-1 p.m. CT session, “Beyond the Basics: Application of HIPAA to Oddly Common Situations in the Healthcare Setting,” will cover how HIPAA applies when law enforcement arrives during an investigation, the presence of ICE activity, fractured family situations, subpoenas, including grand jury subpoenas, and more.
LaDonna Boeckman, a partner at the law firm HeplerBroom, which has offices across Illinois, will present the session with Chelsea Caldwell, an associate attorney. The webinar is offered through the Illinois Society of Healthcare Risk Management (ISHRM) and sponsored by IHA.
The program is designed for healthcare providers, nurses, risk managers and attorneys. Registration is free for ISHRM members and $25 for non-members.
Register today.
Eight Drug Manufacturers Approved for Participation in 340B Pilot Program
The Health Resources and Services Administration (HRSA)
posted on its website that eight drug manufacturers have been approved for participation in the 340B Rebate Model Pilot Program with a start date of Jan. 1, 2026. These plans met the requirements outlined in the
Federal Register Notice. The website includes a list of the drug companies and drugs approved by HRSA for the pilot program. The bottom of the webpage also includes updated FAQs related to the pilot program.
“Under the 340B Rebate Model Pilot Program, covered entities must continue to make purchases through their 340B wholesaler account and must ensure they are only requesting rebates on the above drugs dispensed to 340B eligible patients after a purchase is made,” HRSA said. “Manufacturers should work with their distributor partners to ensure the [wholesale acquisition cost] price is loaded in the 340B wholesaler account where purchases will be made by covered entities to then obtain a rebate.”
“Manufacturers should subsequently work with their distributors to obtain necessary data from the 340B wholesaler account to monitor purchases in that account,” HRSA said. HRSA recommended covered entities and manufacturers maintain auditable records for purchases made subject to the 340B Rebate Model Pilot Program. Both covered entities and manufacturers will continue to be audited by HRSA to ensure compliance with statutory requirements. Rebates will be issued by all approved manufacturer plans based at the unit level.
More information about the program, which HRSA announced July 31, can be found
here.
Blood Pressure Drug Recalled Due to Cancer Risk
More than 580,000 bottles of a commonly used blood pressure medication have been
recalled due to concerns the prazosin hydrochloride capsules may include a cancer-causing chemical. The Food and Drug Administration (FDA) said some of the medication may have potentially carcinogenic impurities that exceed the acceptable safety limit. The FDA has classified this as a Class II recall, the second most serious type of recall, meaning the products could cause temporary or medically reversible health problems. More information on the recall can be found
here.
Microsoft Issues Security Update Addressing Critical Vulnerability
Microsoft released a security update to address a critical remote code execution vulnerability impacting multiple versions of Windows Server Update Services (WSUS) that was not fully eliminated by a previous update,
according to the Cybersecurity and Infrastructure Security Agency (CISA). CISA is strongly urging organizations that use the WSUS system to implement this update, saying failure to implement the recommended mitigations could allow a cyberattacker to take control of a system completely.
Click here to access the WSUS Remote Code Execution Vulnerability guidance.
